| The 2016 revision of the World Health Organization classification of lymphoid neoplasms SH Swerdlow, E Campo, SA Pileri, NL Harris, H Stein, R Siebert, ... Blood, The Journal of the American Society of Hematology 127 (20), 2375-2390, 2016 | 9025 | 2016 |
| Idelalisib and rituximab in relapsed chronic lymphocytic leukemia RR Furman, JP Sharman, SE Coutre, BD Cheson, JM Pagel, P Hillmen, ... New England Journal of Medicine 370 (11), 997-1007, 2014 | 2261 | 2014 |
| Genetics and pathogenesis of diffuse large B-cell lymphoma R Schmitz, GW Wright, DW Huang, CA Johnson, JD Phelan, JQ Wang, ... New England journal of medicine 378 (15), 1396-1407, 2018 | 2091 | 2018 |
| Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project KR Carson, AM Evens, EA Richey, TM Habermann, D Focosi, JF Seymour, ... Blood, The Journal of the American Society of Hematology 113 (20), 4834-4840, 2009 | 1066 | 2009 |
| The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ... Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022 | 1055 | 2022 |
| An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era Z Zhou, LH Sehn, AW Rademaker, LI Gordon, AS LaCasce, ... Blood, The Journal of the American Society of Hematology 123 (6), 837-842, 2014 | 1040 | 2014 |
| Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from … C Casulo, M Byrtek, KL Dawson, X Zhou, CM Farber, CR Flowers, ... Journal of Clinical Oncology 33 (23), 2516-2522, 2015 | 882 | 2015 |
| Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas MS Kaminski, AD Zelenetz, OW Press, M Saleh, J Leonard, ... Journal of clinical oncology 19 (19), 3918-3928, 2001 | 718 | 2001 |
| Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma OA O'Connor, J Wright, C Moskowitz, J Muzzy, B MacGregor-Cortelli, ... Journal of Clinical Oncology 23 (4), 676-684, 2005 | 704 | 2005 |
| Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis AM Petrich, M Gandhi, B Jovanovic, JJ Castillo, S Rajguru, DT Yang, ... Blood, The Journal of the American Society of Hematology 124 (15), 2354-2361, 2014 | 562 | 2014 |
| A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic … CH Moskowitz, SD Nimer, AD Zelenetz, T Trippett, EE Hedrick, DA Filippa, ... Blood, The Journal of the American Society of Hematology 97 (3), 616-623, 2001 | 544 | 2001 |
| Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma T Kewalramani, AD Zelenetz, SD Nimer, C Portlock, D Straus, A Noy, ... Blood 103 (10), 3684-3688, 2004 | 526 | 2004 |
| Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic … OA O'Connor, ML Heaney, L Schwartz, S Richardson, R Willim, ... Journal of Clinical Oncology 24 (1), 166-173, 2006 | 485 | 2006 |
| Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas JM Vose, RL Wahl, M Saleh, AZ Rohatiner, SJ Knox, JA Radford, ... Journal of clinical oncology 18 (6), 1316-1323, 2000 | 441 | 2000 |
| Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303 NL Bartlett, WH Wilson, SH Jung, ED Hsi, MJ Maurer, LD Pederson, ... Journal of clinical oncology 37 (21), 1790-1799, 2019 | 417 | 2019 |
| Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non … CH Moskowitz, JR Bertino, JR Glassman, EE Hedrick, S Hunte, ... Journal of Clinical Oncology 17 (12), 3776-3785, 1999 | 399 | 1999 |
| Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma CH Moskowitz, H Schöder, J Teruya-Feldstein, C Sima, A Iasonos, ... Journal of clinical oncology 28 (11), 1896-1903, 2010 | 398 | 2010 |
| Follicular lymphoma in the United States: first report of the national LymphoCare study JW Friedberg, MD Taylor, JR Cerhan, CR Flowers, H Dillon, CM Farber, ... Journal of Clinical Oncology 27 (8), 1202-1208, 2009 | 395 | 2009 |
| International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) A Younes, P Hilden, B Coiffier, A Hagenbeek, G Salles, W Wilson, ... Annals of Oncology 28 (7), 1436-1447, 2017 | 379 | 2017 |
| Management of adverse events associated with idelalisib treatment: expert panel opinion SE Coutré, JC Barrientos, JR Brown, S de Vos, RR Furman, MJ Keating, ... Leukemia & lymphoma 56 (10), 2779-2786, 2015 | 364 | 2015 |
